Clinical Trial Results: Non-Hodgkin's Lymphoma

Product Name: MabThera/Rituxan [rituximab]
Date of Report: 12/22/2003
Phase: III
An Open-Label, Randomized, Multi-Center Study Comparing Standard Cyclophosphamide, Vincristine, Prednisolone (CVP) Chemotherapy with Rituximab plus CVP (R-CVP) in Patients with Previously Untreated CD20-Positive Follicular Lymphoma (Stage III-IV)

Product Name: MabThera/Rituxan [rituximab]
Date of Report: 2/8/2005
Phase: III
An open-labeled, randomized, multicenter Phase III clinical trial of first-line treatment for patients with CD20-positive diffuse large B-cell non-Hodgkin’s lymphoma with a standard CHOP chemotherapy regimen with or without rituximab (MabThera) (IDEC-C2B8).

Product Name: MabThera/Rituxan [rituximab]
Date of Report: 2/24/2005
Phase: II
Treatment of follicular and mantle cell non-Hodgkin’s lymphoma with anti-CD20 antibody rituximab (IDEC-C2B8) after high-dose chemotherapy with autologous CD34+ enriched peripheral blood stem-cell transplantation.

Product Name: MabThera/Rituxan [rituximab]
Date of Report: 4/1/2005
Phase: III
A randomized intergroup trial of first-line treatment for patients with diffuse large B-cell lymphoma (DLBCL) with a CHOP-like chemotherapy regimen with or without the anti-CD20 antibody rituximab.

Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: II
A Study of MabThera (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin’s Lymphoma

Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: III
A Study of Mabthera (Rituximab) in Patients With Advanced Non-Hodgkin’s Lymphoma

Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: IV
A Study of MabThera (Rituximab) in Patients with HIV-Related Non-Hodgkin’s Lymphoma

Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: IV
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin’s Lymphoma

Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: III
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin’s Lymphoma (NHL)

Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: II
A Study of Induction and Maintenance Treatment with MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas

Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: II
A Study of MabThera (Rituximab) in Patients With Relapsed Centroblastic Centrocytic Non-Hodgkin's Lymphoma

Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: IV
A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.

Product Name: Neulastim [pegfilgrastim]
Date of Report: To be Published
Phase: IV
An Expanded Access Program of Neulastim (Pegfilgrastim) in Patients With Non-Hodgkin's Lymphoma.

Product Name: ocrelizumab
Date of Report: To be Published
Phase: II
A Study of Ocrelizumab in Patients with Follicular Non-Hodgkin’s Lymphoma (NHL)

Product Name: R7159
Date of Report: To be Published
Phase: II
A Dose-Escalating Study of R7159 Monotherapy in Patients With CD20+ Malignant Disease.